Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer Ventures
Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer…
Lucid Diligence Brief: Paradigm to acquire Flatiron’s Clinical Research Business
Lucid Diligence Brief: Paradigm to acquire Flatiron’s Clinical Research…
Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy for lung cancer
Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy…
Lucid Diligence Brief: Circular Genomics $15 million Series A for circular RNA biomarkers
Lucid Diligence Brief: Circular Genomics $15 million Series A for circular RNA…
Lucid Diligence Brief: Protego Biopharma $130M Series B
Lucid Diligence Brief: Protego Biopharma $130M Series B Professional audiences…
Lucid Diligence Brief: Dayra Therapeutics, Versant Ventures and Biogen collaboration
Lucid Diligence Brief: Dayra Therapeutics, Versant Ventures and Biogen…
Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer
Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer…
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration Professional…
Lucid Diligence Brief: Waker BioScience Series A in CGT
Lucid Diligence Brief: Waker BioScience Series A in CGT Professional audiences…
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+ Professional audiences…
Lucid Diligence Brief: Sword Health partners with Greece on AI health "front door"
Lucid Diligence Brief: Sword Health partners with Greece on AI health "front…
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing partnership to advance CLG-001
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing…